Wolfgang Lilleby

  • Consultant
  • +47 22 93 41 89
 

Author network for Wolfgang Lilleby by COREMINE medical


Publications 2018

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W (2018)
Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Urol Oncol (in press)
DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV et al. (2018)
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
JAMA, 319 (9), 896-905
DOI 10.1001/jama.2018.0587, PubMed 29509865

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2018)
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Int J Radiat Oncol Biol Phys, 101 (4), 883-888
DOI 10.1016/j.ijrobp.2018.03.060, PubMed 29976500

Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W (2018)
Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Acta Radiol, 284185118810977 (in press)
DOI 10.1177/0284185118810977, PubMed 30379559

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol (in press)
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Publications 2017

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Publications 2016

Lilleby W, Stensvold A, Dahl AA (2016)
Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer
Acta Oncol, 55 (7), 807-13
DOI 10.3109/0284186X.2015.1127417, PubMed 26959297

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Publications 2015

Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K (2015)
Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Radiat Oncol, 10, 232
DOI 10.1186/s13014-015-0540-3, PubMed 26577452

Lilleby W, Raabe NK, Normann M (2015)
[Re: The problematical prostate cancer]
Tidsskr Nor Laegeforen, 135 (11), 1009
DOI 10.4045/tidsskr.15.0593, PubMed 26080763

Lilleby W, Vlatkovic L, Meza-Zepeda LA, Revheim ME, Hovig E (2015)
Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report
J Med Case Rep, 9, 281
DOI 10.1186/s13256-015-0749-7, PubMed 26654961

Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L (2015)
Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy
Acta Oncol, 54 (10), 1805-13
DOI 10.3109/0284186X.2015.1037008, PubMed 25927504

Raabe NK, Normann M, Lilleby W (2015)
Low-dose-rate brachytherapy for low-grade prostate cancer
Tidsskr Nor Laegeforen, 135 (6), 548-52
DOI 10.4045/tidsskr.13.1404, PubMed 25806763

Solberg A, Angelsen A, Berge V, Lilleby W, Iversen J, Klepp O, Brennhovd B, Johannessen D, Nygård Y, Larsen K, Stensvold A (2015)
[Re: Different guidelines for treatment of prostate cancer]
Tidsskr Nor Laegeforen, 135 (12-13), 1105
DOI 10.4045/tidsskr.15.0652, PubMed 26130530

Publications 2014

Lilleby W, Stensvold A, Dahl AA (2014)
Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up
Acta Oncol, 53 (10), 1380-9
DOI 10.3109/0284186X.2014.916042, PubMed 24844918

Publications 2013

Lilleby W, Stensvold A, Dahl AA (2013)
Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life
Prostate, 73 (10), 1038-47
DOI 10.1002/pros.22651, PubMed 23532709

Lilleby W, Stensvold A, Mills IG, Nesland JM (2013)
Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients
Int J Cancer, 133 (1), 149-55
DOI 10.1002/ijc.28002, PubMed 23280694

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Publications 2012

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
Bother problems in prostate cancer patients after curative treatment
Urol Oncol, 31 (7), 1067-78
DOI 10.1016/j.urolonc.2011.12.020, PubMed 22341412

Publications 2011

Lilleby W, Tafjord G, Raabe NK (2011)
Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer
Int J Radiat Oncol Biol Phys, 83 (3), 933-9
DOI 10.1016/j.ijrobp.2011.08.028, PubMed 22138456

Lilleby W, Willoch F, Stensvold A (2011)
Detection of prostate cancer relapse with PET/CT using a novel radiotracer
Acta Oncol, 51 (3), 397-9
DOI 10.3109/0284186X.2011.614638, PubMed 21936756

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
Prostate, 72 (6), 668-76
DOI 10.1002/pros.21470, PubMed 21809351

Publications 2010

Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W (2010)
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma
Clin Oncol (R Coll Radiol), 23 (5), 339-43
DOI 10.1016/j.clon.2010.11.006, PubMed 21134733

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S (2010)
Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center
Acta Oncol, 50 (3), 408-14
DOI 10.3109/0284186X.2010.492236, PubMed 20586661

Publications 2009

Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
Clin Exp Metastasis, 26 (5), 485-96
DOI 10.1007/s10585-009-9248-9, PubMed 19294521

Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
[Incorrect about hormone treatment in prostatic cancer]
Tidsskr Nor Laegeforen, 129 (5), 429
DOI 10.4045/tidsskr.08.0649, PubMed 19247406

Publications 2008

Berg A, Bruland ØS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W (2008)
Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
Prostate, 68 (15), 1607-14
DOI 10.1002/pros.20826, PubMed 18655095

Raabe NK, Lilleby W, Tafjord G, Aström L (2008)
[High dose rate brachytherapy in prostate cancer in Norway]
Tidsskr Nor Laegeforen, 128 (11), 1275-8
PubMed 18511969

Steinsvik EA, Fosså SD, Lilleby W, Eilertsen K (2008)
Fertility issues in patients with prostate cancer
BJU Int, 102 (7), 793-5
DOI 10.1111/j.1464-410X.2008.07739.x, PubMed 18489529

Publications 2007

Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, Kvalheim G (2007)
Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
Int J Cancer, 120 (8), 1603-9
DOI 10.1002/ijc.22488, PubMed 17230512

Berg A, Lilleby W, Bruland OS, Fosså SD (2007)
10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy
Int J Radiat Oncol Biol Phys, 69 (4), 1074-83
DOI 10.1016/j.ijrobp.2007.04.031, PubMed 17703896

Lilleby W (2007)
Use of bisphosphonates in advanced prostate cancer: Current status
Indian J Urol, 23 (1), 54
DOI 10.4103/0970-1591.30268, PubMed 19675764

Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
Acta Oncol, 46 (8), 1195-7
DOI 10.1080/02841860701367886, PubMed 17851841

Publications 2006

Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD (2006)
[Treatment of hormone-resistant prostate cancer]
Tidsskr Nor Laegeforen, 126 (21), 2798-801
PubMed 17086220

Publications 2005

Bassarova AV, Nesland JM, Sedloev T, Lilleby W, Hristova SL, Trifonov DY, Torlakovic E (2005)
Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53
Int J Surg Pathol, 13 (3), 239-46
DOI 10.1177/106689690501300302, PubMed 16086078

Lilleby W, Fosså SD (2005)
Chemotherapy in metastatic renal cell cancer
World J Urol, 23 (3), 175-9
DOI 10.1007/s00345-004-0469-x, PubMed 15726382

Lilleby W, Sudbø J, Fosså SD (2005)
[Biology and treatment options during the development of prostate cancer]
Tidsskr Nor Laegeforen, 125 (5), 571-4
PubMed 15776028

Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD (2005)
Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma
Int J Cancer, 117 (3), 381-6
DOI 10.1002/ijc.21174, PubMed 15900599

Publications 2003

Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W (2003)
[Breast cancer patients' assessment of waiting time before radiotherapy]
Tidsskr Nor Laegeforen, 123 (12), 1685-6
PubMed 12821991

Fosså SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR (2003)
Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy
Int J Radiat Oncol Biol Phys, 57 (1), 33-41
DOI 10.1016/S0360-3016(03)00428-0, PubMed 12909213

Lilleby W, Dale E, Olsen DR, Gude U, Fosså SD (2003)
Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose
Acta Oncol, 42 (1), 10-4
DOI 10.1080/0891060310002177, PubMed 12665325

Lilleby W, Nesland JM, Fosså SD, Torlakovic G, Waehre H, Kvalheim G (2003)
The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
Int J Cancer, 103 (1), 91-6
DOI 10.1002/ijc.10780, PubMed 12455058

Publications 2002

Fosså A, Lilleby W, Fosså SD, Gaudernack G, Torlakovic G, Berner A (2002)
Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy
Int J Cancer, 99 (1), 100-5
DOI 10.1002/ijc.10286, PubMed 11948499

Torlakovic E, Lilleby W, Torlakovic G, Fosså SD, Chibbar R (2002)
Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score
Hum Pathol, 33 (6), 646-51
DOI 10.1053/hupa.2002.124033, PubMed 12152165

Publications 2001

Lilleby W, Paus E, Skovlund E, Fosså SD (2001)
Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
Prostate, 46 (2), 126-33
PubMed 11170140

Lilleby W, Torlakovic G, Torlakovic E, Skovlund E, Fosså SD (2001)
Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy
Cancer, 92 (2), 311-9
DOI 10.1002/1097-0142(20010715)92:2<311::AID-CNCR1324>3.0.CO;2-H, PubMed 11466684

Publications 2000

Lilleby W, Fosså SD, Knutsen BH, Abildgaard A, Skovlund E, Lien HH (2000)
Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation
Radiother Oncol, 57 (2), 195-200
DOI 10.1016/S0167-8140(00)00219-X, PubMed 11054523

Publications 1999

Lilleby W, Fosså SD, Waehre HR, Olsen DR (1999)
Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy
Int J Radiat Oncol Biol Phys, 43 (4), 735-43
DOI 10.1016/S0360-3016(98)00475-1, PubMed 10098428

Lilleby W, Olsen DR, Foss a SD (1999)
Comparison of radiation side-effects in prostate cancer
Lancet, 353 (9162), 1443
DOI 10.1016/S0140-6736(05)75969-9, PubMed 10227249

Jan 12, 2004 Page visits: 1439